GNRH1 and posterior cortical atrophy: Gonadotropin-releasing hormone (GnRH) agonists (Degarelix) and GnRH antagonists (buserelin, goserelin, leuprorelin, and triptorelin) are initial hormonal therapies for PCa but these are associated with an increased risk of adverse cardiovascular events.